PPI Selection for Patients on Dual Antiplatelet Therapy

ESC Guideline Recommendations

The 2017 European Society of Cardiology (ESC) guidelines give a Class I recommendation that a proton‑pump inhibitor (PPI) should be co‑prescribed with dual antiplatelet therapy (DAPT) to reduce gastrointestinal bleeding risk【1】.

ESC guideline‑driven drug‑interaction studies show omeprazole and esomeprazole have the highest propensity for clinically relevant inhibition of CYP2C19, which is needed to activate clopidogrel, whereas pantoprazole and rabeprazole have the lowest propensity【1】【2】【3】【4】.
Consequently, omeprazole and esomeprazole should be avoided when clopidogrel‑based DAPT is used because they strongly inhibit CYP2C19 metabolism and may diminish clopidogrel’s antiplatelet effect【1】.
Pantoprazole and rabeprazole are the preferred PPIs for patients on clopidogrel‑based DAPT, as they exhibit minimal CYP2C19 interaction and preserve antiplatelet efficacy【1】【2】【3】.

Observational studies of PPI use with clopidogrel have yielded inconsistent associations with cardiovascular events, with the majority showing no significant increase in risk【5】 (Level B evidence).
The only randomized controlled trial evaluating omeprazole with clopidogrel demonstrated a reduction in gastrointestinal bleeding without a statistically significant rise in cardiovascular events, although the confidence interval allowed for up to a 44 % relative increase in cardiovascular risk【5】 (Level A evidence).
A study of H2‑receptor antagonists reported that famotidine may be used in lower‑risk patients, but PPIs remain more effective for ulcer prevention; cimetidine should be avoided because it also inhibits CYP2C19【5】.
Evidence indicates that withholding PPI therapy in high‑risk patients is not advisable; the benefit of bleeding risk reduction outweighs the theoretical cardiovascular risk【5】.

First‑line PPI choice: prescribe pantoprazole or rabeprazole for any patient on clopidogrel‑based DAPT【1】.
Avoid: omeprazole and esomeprazole when clopidogrel is part of the regimen【1】.
When newer P2Y12 inhibitors (ticagrelor, prasugrel) are used, the relevance of PPI selection diminishes because these agents do not require CYP2C19 activation【1】.

Do not reflexively prescribe omeprazole merely because it was the PPI studied in early trials; ESC guidance highlights its higher interaction risk【1】【2】【3】.
Recognize that PPIs are not a homogeneous class; the degree of CYP2C19 inhibition varies markedly among agents, influencing antiplatelet efficacy【1】.